• Earlier in February 2026, GE HealthCare received FDA 510(k) clearance for three MR innovations, the helium-free SIGNA Sprint with Freelium, the high-performance SIGNA Bolt 3T scanner, and the AI-driven SIGNA One workflow ecosystem, aimed at improving imaging efficiency, sustainability, and access across diverse care settings.
• This combination of helium independence, reduced power and space requirements, and end-to-end AI workflow support could meaningfully influence how hospitals think about long-term MRI fleet upgrades and operating costs.
• Next, we’ll examine how this new wave of AI-enabled, helium-light MRI systems may reshape GE HealthCare’s existing investment narrative.

AI is about to change healthcare. These 28 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

GE HealthCare Technologies Investment Narrative Recap

To own GE HealthCare, you need to believe large health systems will keep investing in advanced imaging, and that the company can convert its innovation pipeline into steady earnings while managing tariff and China-related pressures. The new AI-enabled, helium-light MRI portfolio may support the near term product catalyst around high impact imaging launches, but it does not materially change the key risk that competitor advances could still pressure market share and pricing.

Among recent announcements, the expanded US$35 million BARDA-backed program for AI-powered ultrasound is especially relevant, because it reinforces the same theme as the new SIGNA MR clearances: GE HealthCare is leaning into AI and workflow automation across modalities to support higher utilization of installed equipment. Together, these developments tie directly into the existing catalyst of a broader product pipeline that aims to deepen customer relationships and support recurring digital and service revenue.

Yet, despite this innovation push, the risk that competitor product advances could erode GE HealthCare’s imaging share is something investors should be aware of...

GE HealthCare Technologies' narrative projects $22.7 billion revenue and $2.5 billion earnings by 2028.

Uncover how GE HealthCare Technologies' forecasts yield a $93.25 fair value, a 11% upside to its current price.

Exploring Other Perspectives

Four fair value estimates from the Simply Wall St Community span roughly US$62 to US$117 per share, underscoring how differently investors can view the same earnings outlook. When you set those views against GE HealthCare’s heavy reliance on new product launches in MR and other imaging, it becomes clear why comparing several independent perspectives on the company’s prospects can be useful.

Explore 4 other fair value estimates on GE HealthCare Technologies - why the stock might be worth 26% less than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your GE HealthCare Technologies research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free GE HealthCare Technologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate GE HealthCare Technologies' overall financial health at a glance.

Seeking Other Investments?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Uncover the next big thing with 31 elite penny stocks that balance risk and reward.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 22 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Capitalize on the AI infrastructure supercycle with our selection of the 33 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.